These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35705913)

  • 1. Risk of selection bias assessment in the NINDS rt-PA stroke study.
    Garg R; Mickenautsch S
    BMC Med Res Methodol; 2022 Jun; 22(1):172. PubMed ID: 35705913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
    Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
    BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
    Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
    Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
    Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
    Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
    J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteplase and ischaemic stroke: have new reviews of old data helped?
    Lindley RI; Wardlaw JM; Sandercock PA
    Lancet Neurol; 2005 Apr; 4(4):249-53. PubMed ID: 15778104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.
    ; Levine SR; Khatri P; Broderick JP; Grotta JC; Kasner SE; Kim D; Meyer BC; Panagos P; Romano J; Scott P;
    Stroke; 2013 Sep; 44(9):2500-5. PubMed ID: 23847249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
    Kwiatkowski T; Libman R; Tilley BC; Lewandowski C; Grotta JC; Lyden P; Levine SR; Brott T;
    Ann Emerg Med; 2005 Apr; 45(4):377-84. PubMed ID: 15795715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
    Patel SC; Levine SR; Tilley BC; Grotta JC; Lu M; Frankel M; Haley EC; Brott TG; Broderick JP; Horowitz S; Lyden PD; Lewandowski CA; Marler JR; Welch KM;
    JAMA; 2001 Dec; 286(22):2830-8. PubMed ID: 11735758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
    Stroke; 2000 Dec; 31(12):2912-9. PubMed ID: 11108748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects of thrombolytic therapy for acute ischemic stroke].
    Nakashima T; Minematsu K
    Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
    Hemmen TM; Rapp KS; Emond JA; Raman R; Lyden PD
    J Stroke Cerebrovasc Dis; 2010; 19(4):290-3. PubMed ID: 20471855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
    National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
    Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.
    Grotta JC; Welch KM; Fagan SC; Lu M; Frankel MR; Brott T; Levine SR; Lyden PD
    Stroke; 2001 Mar; 32(3):661-8. PubMed ID: 11239184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Kumar G; Uhrig D; Fowler S; DeLaney MC; Alexandrov AV
    CNS Drugs; 2015 Aug; 29(8):659-67. PubMed ID: 26251162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
    Balucani C; Levine SR; Khoury JC; Khatri P; Saver JL; Broderick JP
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):894-901. PubMed ID: 26825352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
    Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
    J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.
    Marler JR; Tilley BC; Lu M; Brott TG; Lyden PC; Grotta JC; Broderick JP; Levine SR; Frankel MP; Horowitz SH; Haley EC; Lewandowski CA; Kwiatkowski TP
    Neurology; 2000 Dec; 55(11):1649-55. PubMed ID: 11113218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.